Alloy Therapeutics

Wheeler Bio is a biomanufacturing company founded in 2020 by Jesse McCool in Oklahoma City, focused on accelerating the translation of therapeutic innovations into clinical applications. The company offers a unique platform that integrates pre-clinical discovery with biomanufacturing processes, addressing critical gaps that often hinder the development of new therapies. By providing access to comprehensive discovery-to-IND programs, Wheeler Bio enables biopharma companies to streamline their path to clinical trials. Its Portable CMC platform ensures rapid and high-quality biomanufacturing, allowing clients to achieve a predictable and efficient route to bringing therapies to market.

Wheeler Bio is a biomanufacturing company founded in 2020 by Jesse McCool in Oklahoma City, focused on accelerating the translation of therapeutic innovations into clinical applications. The company offers a unique platform that integrates pre-clinical discovery with biomanufacturing processes, addressing critical gaps that often hinder the development of new therapies. By providing access to comprehensive discovery-to-IND programs, Wheeler Bio enables biopharma companies to streamline their path to clinical trials. Its Portable CMC platform ensures rapid and high-quality biomanufacturing, allowing clients to achieve a predictable and efficient route to bringing therapies to market.

Vernal Biosciences is an mRNA manufacturing company that specializes in providing high-purity mRNA for research and clinical applications. The company leverages advanced processing and analytical methods to streamline the manufacturing process, significantly reducing the time and uncertainty typically associated with developing advanced therapeutics. Vernal Biosciences offers its services on a transactional basis, focusing on mRNA and lipid nanoparticle-mRNA (LNP-mRNA) production for use in various research contexts involving cells, animals, and humans. This approach enables research professionals to access on-demand, high-purity mRNA, supporting efficient drug discovery and development while minimizing the need for substantial investments in specialized teams and facilities.

Tegmine Therapeutics is a private, seed-stage biotechnology company focused on developing antibody-based therapeutics that target proteins and their disease-related glycan modifications. The company employs a unique platform that integrates biology, mass spectrometry, and machine learning to identify tumor-specific protein modifications responsible for disease progression and severity. This innovative approach aims to facilitate the creation of next-generation antibody drugs that are specifically designed to target tumors while minimizing damage to healthy tissues. Through its research and development efforts, Tegmine Therapeutics seeks to contribute to more sustainable cancer and tumor therapies, enhancing treatment efficacy and patient outcomes.

Mytide Therapeutics is a biotechnology company focused on the development and production of peptides for various applications. By leveraging advanced biopolymer fabrication technology, Mytide aims to address challenges in synthesizing and purifying specific classes of peptides. The company utilizes predictive analytics and machine learning to industrialize the production and expedite the discovery of biological therapeutics. This approach is designed to enhance access to life-saving therapies for patients suffering from serious illnesses, including metabolic conditions, cancer, and inflammatory disorders. Mytide also collaborates with partners to identify beneficial peptide modifications and construct diverse peptide libraries, providing them with access to a cloud platform for efficient ordering and data management.

Wheeler Bio is a biomanufacturing company founded in 2020 by Jesse McCool in Oklahoma City, focused on accelerating the translation of therapeutic innovations into clinical applications. The company offers a unique platform that integrates pre-clinical discovery with biomanufacturing processes, addressing critical gaps that often hinder the development of new therapies. By providing access to comprehensive discovery-to-IND programs, Wheeler Bio enables biopharma companies to streamline their path to clinical trials. Its Portable CMC platform ensures rapid and high-quality biomanufacturing, allowing clients to achieve a predictable and efficient route to bringing therapies to market.

deepCDR Biologics AG is a biotechnology company established in 2018 and headquartered in Basel, Switzerland. The company specializes in antibody optimization and discovery services, utilizing advanced technologies to deliver scalable solutions for its clients. By focusing on innovative approaches in biologics, deepCDR Biologics aims to enhance the development process of therapeutic antibodies, catering to the growing demands of the biopharmaceutical industry.

Wheeler Bio is a biomanufacturing company founded in 2020 by Jesse McCool in Oklahoma City, focused on accelerating the translation of therapeutic innovations into clinical applications. The company offers a unique platform that integrates pre-clinical discovery with biomanufacturing processes, addressing critical gaps that often hinder the development of new therapies. By providing access to comprehensive discovery-to-IND programs, Wheeler Bio enables biopharma companies to streamline their path to clinical trials. Its Portable CMC platform ensures rapid and high-quality biomanufacturing, allowing clients to achieve a predictable and efficient route to bringing therapies to market.

Vernal Biosciences is an mRNA manufacturing company that specializes in providing high-purity mRNA for research and clinical applications. The company leverages advanced processing and analytical methods to streamline the manufacturing process, significantly reducing the time and uncertainty typically associated with developing advanced therapeutics. Vernal Biosciences offers its services on a transactional basis, focusing on mRNA and lipid nanoparticle-mRNA (LNP-mRNA) production for use in various research contexts involving cells, animals, and humans. This approach enables research professionals to access on-demand, high-purity mRNA, supporting efficient drug discovery and development while minimizing the need for substantial investments in specialized teams and facilities.